Quoin Pharmaceuticals, Ltd.
QNRX
$-0.08
Change (1 day)
$6.18
Year High
$0.43
Year Low
Categories
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Revenue of Quoin Pharmaceuticals, Ltd. (QNRX)
Revenue in 2023 (TTM): $
According to Quoin Pharmaceuticals, Ltd.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Quoin Pharmaceuticals, Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-103,438 | $-9,274,798 | $-8,664,189 | $-8,686,573 |
| 2022 | $ | $-103,635 | $-8,744,652 | $-9,381,496 | $-9,277,453 |
| 2021 | $ | $-104,115 | $-21,373,325 | $-21,462,588 | $-8,518,668 |
| 2020 | $ | $-104,773 | $-2,005,293 | $-2,095,364 | $-1,764,052 |
| 2019 | $ | $-227,055 | $-1,539,691 | $-1,560,401 | $-1,560,401 |
| 2018 | $-280,000 | $-405,720 | $-5,468,582 | $15.32 M | $15.32 M |
| 2017 | $ | $-104,223 | $-7,803,293 | $10.17 M | $10.17 M |
| 2016 | $-280,000 | $-369,130 | $-3,905,798 | $15.32 M | $15.32 M |
| 2015 | $ | $-18,271 | $-2,599,491 | $-2,617,764 | $-2,617,764 |